TY - JOUR
T1 - Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy
AU - Bache, Matthias
AU - Holzapfel, Daniel
AU - Kappler, Matthias
AU - Holzhausen, Hans Jürgen
AU - Taubert, Helge
AU - Dunst, Jürgen
AU - Hänsgen, Gabriele
N1 - Funding Information:
We thank our colleagues from the Department of Radiotherapy and Institute of Pathology for contributing to this study and for their continuous support. We are very thankful to Clare Burns-Klein for revising the manuscript. This work was supported by the Deutsche Krebshilfe (grant number: 106764) and by the State Saxony-Anhalt (grant number: 3584A and B/1104M).
Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2007/1
Y1 - 2007/1
N2 - Background: Survivin is strongly overexpressed in the vast majority of cancers. Initial investigations suggest a role for Survivin in radiation resistance. In this study, we investigate the effect of Survivin expression on clinical outcome and its relationship to tumor oxygenation parameters, expression of Hif-1α and anemia in patients with advanced cervical cancers treated with radiotherapy. Material and methods: Biopsies of 44 patients with cervical cancers (Stage IIB: n = 9; Stage IIIB: n = 31; Stage IVA: n = 4) treated with radiotherapy were assessed by immunochemistry for expression of Survivin. Relation of Survivin to pretreatment tumor oxygenation parameters (HF5, pO2), hemoglobin (hb) level, Hif-1α expression and clinical parameters were investigated. Results: Survivin expression was detected in all tumors of the 44 patients. Seven showed a strong expression and 37 have moderate Survivin expression. Patients whose tumors showed moderate Survivin expression had a 5-year overall survival of 66%. However, only one of the seven patients with strong Survivin expression was alive 45 months after treatment. In a Cox regression analysis, Survivin expression was correlated to poor overall survival (p = 0.02, RR = 3.3). There was no relationship between Survivin expression and pO2 or HF5, but rather an inverse correlation with hemoglobin level (p = 0.04). Furthermore, for six of the seven tumors with a high Survivin expression, Hif-1α was detected. Conclusion: Survivin protein expression is linked with anemia and prognosis in advanced cervical carcinoma of patients treated by radiotherapy.
AB - Background: Survivin is strongly overexpressed in the vast majority of cancers. Initial investigations suggest a role for Survivin in radiation resistance. In this study, we investigate the effect of Survivin expression on clinical outcome and its relationship to tumor oxygenation parameters, expression of Hif-1α and anemia in patients with advanced cervical cancers treated with radiotherapy. Material and methods: Biopsies of 44 patients with cervical cancers (Stage IIB: n = 9; Stage IIIB: n = 31; Stage IVA: n = 4) treated with radiotherapy were assessed by immunochemistry for expression of Survivin. Relation of Survivin to pretreatment tumor oxygenation parameters (HF5, pO2), hemoglobin (hb) level, Hif-1α expression and clinical parameters were investigated. Results: Survivin expression was detected in all tumors of the 44 patients. Seven showed a strong expression and 37 have moderate Survivin expression. Patients whose tumors showed moderate Survivin expression had a 5-year overall survival of 66%. However, only one of the seven patients with strong Survivin expression was alive 45 months after treatment. In a Cox regression analysis, Survivin expression was correlated to poor overall survival (p = 0.02, RR = 3.3). There was no relationship between Survivin expression and pO2 or HF5, but rather an inverse correlation with hemoglobin level (p = 0.04). Furthermore, for six of the seven tumors with a high Survivin expression, Hif-1α was detected. Conclusion: Survivin protein expression is linked with anemia and prognosis in advanced cervical carcinoma of patients treated by radiotherapy.
UR - http://www.scopus.com/inward/record.url?scp=33846020971&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2006.07.011
DO - 10.1016/j.ygyno.2006.07.011
M3 - Journal articles
C2 - 16919715
AN - SCOPUS:33846020971
SN - 0090-8258
VL - 104
SP - 139
EP - 144
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -
